Boehringer Ingelheim: Asthma trials

The registry lists 62 Asthma studies with Boehringer Ingelheim as lead sponsor. 0 are open to participants now and 37 have results posted.

Phase 1 7Phase 2 26Phase 3 17Phase 4 6No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Exacerbation Risk in AsthmaCompletedNCT05501639Results posted
• Evaluation of Safety and Tolerability of BI 894416 in Patients With Mild AsthmaCompletedNCT03971539Phase 1Results posted
• Impact of Tiotropium Add-on Therapy in Patients With AsthmaCompletedNCT03964220Results posted
• Characteristics of Pts Initiating Spiriva Respimat in AsthmaCompletedNCT03692676Results posted
• Specific Use-Result of Spiriva Respimat® in AsthmaticsCompletedNCT03188120Results posted
• BI 443651 Methacholine ChallengeCompletedNCT03135899Phase 1Results posted
• Specific Use-result Surveillance of Spiriva Respimat in AsthmaticsCompletedNCT02489981Results posted
• Asthma Biomarker StudyCompletedNCT02392481Results posted
• Comparison of Two Daily Dose Regimens of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for 4 Weeks on Top of Maintenance Therapy With Inhaled Corticosteroid Controller MedicationCompletedNCT01696071Phase 2Results posted
• Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Severe Persistent AsthmaCompletedNCT01634152Phase 3Results posted
• Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent AsthmaCompletedNCT01634139Phase 3Results posted
• Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent AsthmaCompletedNCT01634113Phase 2Results posted
• Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS)TerminatedNCT01397201Phase 2Results posted
• Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) TherapyTerminatedNCT01397162Phase 2Results posted
• Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).TerminatedNCT01396278Phase 2Results posted
• A Study to Evaluate Efficacy and Safety of Tiotropium in Children 6 to 11 Years Old With Moderate AsthmaCompletedNCT01383499Phase 2Results posted
• Evaluation of Tiotropium 2.5 and 5 µg Once Daily Delivered Via the Respimat Inhaler Compared to Placebo in Patient With Moderate to Severe Persistent AsthmaCompletedNCT01340209Phase 3Results posted
• Efficacy and Safety of 2 Doses of Tiotropium Via Respimat in Adult Patients With Mild Persistent AsthmaCompletedNCT01316380Phase 3Results posted
• A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat® Inhaler in Patients With Moderate to Severe AsthmaCompletedNCT01311661Phase 2Results posted
• Efficacy and Safety of 2 Doses of Tiotropium Respimat Compared to Placebo in Adolescents With Severe Persistent AsthmaCompletedNCT01277523Phase 3Results posted
• Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent AsthmaCompletedNCT01257230Phase 3Results posted
• Randomised, Double- Blind, Cross-over Efficacy and Safety Comparison of Three Different Doses of Tiotropium Administered Once Daily Versus Placebo in Patients With Moderate Persistent Asthma.CompletedNCT01233284Phase 2Results posted
• Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma IICompletedNCT01172821Phase 3Results posted
• Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma ICompletedNCT01172808Phase 3Results posted
• A Randomised, Double- Blind, Placebo Controlled, Cross-over Efficacy and Safety Comparison of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for Four Weeks in Patients With Moderate Persistent AsthmaCompletedNCT01152450Phase 2Results posted
• Efficacy and Safety of 3 Doses of Tiotropium Compared to Placebo in Adolescents (12 to 17 Yrs) With Moderate AsthmaCompletedNCT01122680Phase 2Results posted
• BI 671800 in Asthmatic Patients on Inhaled CorticosteroidsCompletedNCT01103349Phase 2Results posted
• BI 671800 ED in Steroid-naive Asthmatic PatientsCompletedNCT01092143Phase 2Results posted
• Bi 671800 in Asthmatic Patients on Inhaled CorticosteroidsCompletedNCT01090024Phase 2Results posted
• A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma.CompletedNCT01013753Phase 2Results posted
• Efficacy (Bronchoprotection) and Safety of Orally Inhaled BI 1744 CL in Patients With Intermittent AsthmaCompletedNCT00928668Phase 2Results posted
• 4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe AsthmaCompletedNCT00818454Phase 2Results posted
• Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II)CompletedNCT00776984Phase 3Results posted
• Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I)CompletedNCT00772538Phase 3Results posted
• Efficacy and Safety of 4 Weeks of Treatment With Inhaled BI 1744 CL in Patients With AsthmaCompletedNCT00467740Phase 2Results posted
• Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Patients With COPD.CompletedNCT00452400Phase 2Results posted
• Efficacy and Safety of Tiotropium and Salmeterol in Moderate Persistent Asthma Patients Homozygous for B16-Arg/ArgCompletedNCT00350207Phase 2Results posted
• The Effect of BIIL 284 BS on Induced-sputum Variables in Patients With Bronchial AsthmaCompletedNCT02249312Phase 2
• Study to Assess the Efficacy of Ipratropium Bromide Associated With High Dose Salbutamol by Repeated Nebulisation Versus Repeat Nebulisation of Salbutamol Alone, in Acute Asthmatic Attacks in Young ChildrenTerminatedNCT02235428Phase 4
• Serial Lung Function Measurements in Healthy and Mild Asthmatic Adults After Oral Inhalation of Ethanolic Solutions Containing Two Concentrations of the Excipient Butylated Hydroxytoluene (BHT) Administered With the Respimat® B (RMT-B)CompletedNCT02220673Phase 1
• Combivent vs. Salbutamol in Patients With Metacholine Induced BronchospasmCompletedNCT02182713Phase 4
• Efficacy and Safety of Combivent® Aerosol and Spacer, in Adult Patients With Moderate to Severe Asthma CrisisTerminatedNCT02182700Phase 3
• A Long-term Study of Ba253BINEB in Patients With Bronchial AsthmaCompletedNCT02182661Phase 3
• Safety and Efficacy of Berodual® Inhaled Via Respimat® Compared to MDI (Metered Dose Inhaler) in Pediatric Patients With AsthmaCompletedNCT02182505Phase 3
• Safety and Efficacy of Berodual® Respimat® Compared to Berodual® MDI (Metered Dose Inhaler) in Asthma PatientsCompletedNCT02182479Phase 3
• Efficacy and Safety Study Comparing Respimat ® Budesonide With Turbohaler ® Budesonide in Symptomatic Adult Moderate to Severe Asthmatics Requiring Inhaled Corticosteroids and Bronchodilator TherapyCompletedNCT02181335Phase 3
• Effect on Fenoterol Metered Dose Inhaler on the Beta-receptor Population on Lymphocytes in Patients With Bronchial AsthmaTerminatedNCT02177370Phase 3
• Berodual® Respimat® Versus Berodual® Metered Aerosol (MA) Inhaler in Patients With Asthma, Chronic Obstructive Pulmonary Disease, or Mixed ConditionCompletedNCT02173795Phase 3
• Multiple Rising Oral Doses of BI 1060469 in Healthy Subjects and Mild Asthma PatientsCompletedNCT02126865Phase 1
• Multiple Rising Dose Study of BI 144807 Powder in Bottle in Mild Asthmatic PatientsCompletedNCT01651598Phase 1
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1021958 in Otherwise Healthy Controlled Asthmatic SubjectsCompletedNCT01629849Phase 1
• Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled CorticosteroidsWithdrawnNCT01458912Phase 2
• Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Short Acting Beta-2 Agonist (SABA) Therapy AloneWithdrawnNCT01458886Phase 2
• Olodaterol Bridging Study in AsthmaWithdrawnNCT01428622Phase 2
• Single Rising Dose (SRD), Multiple Rising Dose (MRD) Study of BI 671800 in Healthy Asian VolunteersCompletedNCT01216384Phase 1
• Randomized, Placebo Controlled, Crossover Study in an Environmental Challenge Chamber to Assess Safety & Efficacy of Three Oral Doses of BI 671800 Versus Fluticasone Propionate and Montelukast in Sensitive Seasonal Allergic Rhinitis Patients Out of SeasonCompletedNCT01007721Phase 2
• An Efficacy and Safety Evaluation of Tiotropium add-on Therapy in Patients With Severe Persistent AsthmaCompletedNCT00365560Phase 2
• A Comparison of Combivent UDV (Ipratropium 500mcg and Salbutamol 2.5mg) and Salbutamol UDV Alone (2.5mg)CompletedNCT00273962Phase 4
• Evaluation of the Respimat Inhaler vs. a HFA MDI Using Berodual in Patients With COPD With Poor MDI Technique.CompletedNCT00267917Phase 4
• Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00153075Phase 4
• Efficacy and Safety of Tiotropium in Patients With COPD and Concomitant Diagnosis of AsthmaCompletedNCT00152984Phase 4
• Combivent® CFC Metered Dose Inhaler (MDI) in Moderate to Severe AsthmaCompletedNCT00096616Phase 2